Canopy Growth Corporation (CGC)
Healthcare
- Fundamental
- 1
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 1 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry. Independent of that hard block, the chart remains weak with price below SMA20/50/200, EMA9/21, and daily VWAP.
Company overview
Canopy Growth Corporation, headquartered in Smiths Falls, Canada, is involved in the cultivation, marketing, and retail of cannabis and hemp-derived products for recreational and therapeutic use. The company operates through two main divisions: Global Cannabis and Other Consumer Products, offering a range of products such as dried cannabis flower, extracts, infused beverages, and vape cartridges under brands like Tweed and Spectrum Therapeutics.
Fundamental
very weakCanopy Growth shows weak fundamentals with ongoing losses, negative cash flow, and elevated regulatory risks.
Canopy Growth remains a high-risk, loss-making cannabis operator: TTM net margin is -84.76% and EBITDA margin is -20.42%, with negative free cash flow (FCF yield about -30.62%). SEC filings describe prior going-concern pressure, a term-loan minimum-cash covenant, a material internal-control weakness/restatement, and ongoing SEC investigation/class actions. Liquidity improved (current ratio ~3.34), but the discounted-cash-flow outputs are negative, offering no valuation backstop. Overall: speculative turnaround profile.
Sentiment
fairMedia sentiment is mixed, with no severe legal issues but conflicting narratives post-earnings.
CGC’s only near-term actionable catalyst is the FY2026/Q4 earnings release on 2026-06-15 (announced), but last ~14d media tone is mixed and slightly weaker than the 30–90d baseline as coverage highlights a large loss and financial-restatement uncertainty alongside segment revenue growth. Red-Flag Screen: a moderate conflicting-signal setup (bullish company framing vs more cautious/bearish headline reaction) caps the score at 3; no court cases surfaced and no regulator-confirmed investigation was identified from available legal tooling (investigation analyzer text extraction failed).
Technical
very weakThe technical outlook is bearish, with price below key averages and indicators confirming a strong downtrend.
Technical score is 1 because short-term structure is bearish and broken, not bullish. Price is below all key moving averages and VWAP, MACD is below zero, and ADX confirms a strong downtrend despite oversold oscillators.
You’re looking at 2026-06-22 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.